Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology

Peter L. Greenberg; Richard M. Stone; Aref Al-Kali; Stefan K. Barta; Rafael Bejar; John M. Bennett; Hetty Carraway; Carlos M. De Castro; H. Joachim Deeg; Amy E. DeZern; Amir T. Fathi; Olga Frankfurt; Karin Gaensler; Guillermo Garcia-Manero; Elizabeth A. Griffiths; David Head; Ruth Horsfall; Robert A. Johnson; Mark Juckett; Virginia M. Klimek; Rami Komrokji; Lisa A. Kujawski; Lori J. Maness; Margaret R. O'Donnell; Daniel A. Pollyea; Paul J. Shami; Brady L. Stein; Alison R. Walker; Peter Westervelt; Amer Zeidan; Dorothy A. Shead; Courtney Smith

doi:10.6004/jnccn.2017.0007

Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology

Peter L. Greenberg, Richard M. Stone, Aref Al-Kali, Stefan K. Barta, Rafael Bejar, John M. Bennett, Hetty Carraway, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Amir T. Fathi, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Ruth Horsfall, Robert A. Johnson, Mark Juckett, Virginia M. KlimekRami Komrokji, Lisa A. Kujawski, Lori J. Maness, Margaret R. O'Donnell, Daniel A. Pollyea, Paul J. Shami, Brady L. Stein, Alison R. Walker, Peter Westervelt, Amer Zeidan, Dorothy A. Shead, Courtney Smith

Research output: Contribution to journal › Review article › peer-review

241 Scopus citations

Abstract

The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, lowintensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.

Original language	English
Pages (from-to)	60-87
Number of pages	28
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	15
Issue number	1
DOIs	https://doi.org/10.6004/jnccn.2017.0007
State	Published - Jan 1 2017

Access to Document

10.6004/jnccn.2017.0007

Cite this

Greenberg, P. L., Stone, R. M., Al-Kali, A., Barta, S. K., Bejar, R., Bennett, J. M., Carraway, H., De Castro, C. M., Deeg, H. J., DeZern, A. E., Fathi, A. T., Frankfurt, O., Gaensler, K., Garcia-Manero, G., Griffiths, E. A., Head, D., Horsfall, R., Johnson, R. A., Juckett, M., ... Smith, C. (2017). Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 15(1), 60-87. https://doi.org/10.6004/jnccn.2017.0007

@article{700d9b1fe91a4985b459c4804eb84654,

title = "Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology",

abstract = "The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, lowintensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.",

author = "Greenberg, {Peter L.} and Stone, {Richard M.} and Aref Al-Kali and Barta, {Stefan K.} and Rafael Bejar and Bennett, {John M.} and Hetty Carraway and {De Castro}, {Carlos M.} and Deeg, {H. Joachim} and DeZern, {Amy E.} and Fathi, {Amir T.} and Olga Frankfurt and Karin Gaensler and Guillermo Garcia-Manero and Griffiths, {Elizabeth A.} and David Head and Ruth Horsfall and Johnson, {Robert A.} and Mark Juckett and Klimek, {Virginia M.} and Rami Komrokji and Kujawski, {Lisa A.} and Maness, {Lori J.} and O'Donnell, {Margaret R.} and Pollyea, {Daniel A.} and Shami, {Paul J.} and Stein, {Brady L.} and Walker, {Alison R.} and Peter Westervelt and Amer Zeidan and Shead, {Dorothy A.} and Courtney Smith",

note = "Publisher Copyright: {\textcopyright} JNCCN-Journal of the National Comprehensive Cancer Network.",

year = "2017",

month = jan,

day = "1",

doi = "10.6004/jnccn.2017.0007",

language = "English",

volume = "15",

pages = "60--87",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "1",

}

Greenberg, PL, Stone, RM, Al-Kali, A, Barta, SK, Bejar, R, Bennett, JM, Carraway, H, De Castro, CM, Deeg, HJ, DeZern, AE, Fathi, AT, Frankfurt, O, Gaensler, K, Garcia-Manero, G, Griffiths, EA, Head, D, Horsfall, R, Johnson, RA, Juckett, M, Klimek, VM, Komrokji, R, Kujawski, LA, Maness, LJ, O'Donnell, MR, Pollyea, DA, Shami, PJ, Stein, BL, Walker, AR, Westervelt, P, Zeidan, A, Shead, DA & Smith, C 2017, 'Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 15, no. 1, pp. 60-87. https://doi.org/10.6004/jnccn.2017.0007

TY - JOUR

T1 - Myelodysplastic syndromes, version 2.2017

T2 - Clinical practice guidelines in oncology

AU - Greenberg, Peter L.

AU - Stone, Richard M.

AU - Al-Kali, Aref

AU - Barta, Stefan K.

AU - Bejar, Rafael

AU - Bennett, John M.

AU - Carraway, Hetty

AU - De Castro, Carlos M.

AU - Deeg, H. Joachim

AU - DeZern, Amy E.

AU - Fathi, Amir T.

AU - Frankfurt, Olga

AU - Gaensler, Karin

AU - Garcia-Manero, Guillermo

AU - Griffiths, Elizabeth A.

AU - Head, David

AU - Horsfall, Ruth

AU - Johnson, Robert A.

AU - Juckett, Mark

AU - Klimek, Virginia M.

AU - Komrokji, Rami

AU - Kujawski, Lisa A.

AU - Maness, Lori J.

AU - O'Donnell, Margaret R.

AU - Pollyea, Daniel A.

AU - Shami, Paul J.

AU - Stein, Brady L.

AU - Walker, Alison R.

AU - Westervelt, Peter

AU - Zeidan, Amer

AU - Shead, Dorothy A.

AU - Smith, Courtney

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, lowintensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.

AB - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, lowintensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.

UR - http://www.scopus.com/inward/record.url?scp=85009133609&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2017.0007

DO - 10.6004/jnccn.2017.0007

M3 - Review article

C2 - 28040720

AN - SCOPUS:85009133609

SN - 1540-1405

VL - 15

SP - 60

EP - 87

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 1

ER -

Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology

Abstract

Access to Document

Other files and links

Fingerprint

Cite this